| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40263-016-0330-Y |
| P698 | PubMed publication ID | 27003694 |
| P50 | author | Gillian M Keating | Q62563919 |
| P2860 | cites work | Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review | Q24675909 |
| MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective | Q28083929 | ||
| Stability, precision, and near-24-hour period of the human circadian pacemaker | Q28138096 | ||
| Phototransduction by retinal ganglion cells that set the circadian clock | Q28217956 | ||
| Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review | Q28382767 | ||
| Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg | Q28382973 | ||
| Blacks (African Americans) have shorter free-running circadian periods than whites (Caucasian Americans) | Q28389000 | ||
| Human tau in an ultradian light-dark cycle | Q28396732 | ||
| Melatonin administration can entrain the free-running circadian system of blind subjects | Q33884480 | ||
| Entrainment of free-running circadian rhythms by melatonin in blind people | Q33921061 | ||
| Light, melatonin and the sleep-wake cycle | Q33921442 | ||
| The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. | Q34272772 | ||
| Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. | Q34894399 | ||
| Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment | Q35565192 | ||
| Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular S | Q36090692 | ||
| Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients | Q38271225 | ||
| Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse | Q38599874 | ||
| Non-24-Hour Sleep-Wake Rhythm Disorder in Sighted and Blind Patients | Q38633467 | ||
| Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies | Q40515321 | ||
| Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials | Q40952954 | ||
| Tasimelteon: a selective and unique receptor binding profile | Q41656783 | ||
| Entraining the free-running circadian clocks of blind people. | Q47919878 | ||
| Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist | Q47982327 | ||
| Absolute Bioavailability of Tasimelteon | Q47996004 | ||
| P433 | issue | 5 | |
| P921 | main subject | non-24-hour sleep-wake disorder | Q1773215 |
| sleep-wake disorder | Q54972453 | ||
| P304 | page(s) | 461-468 | |
| P577 | publication date | 2016-03-22 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals | |
| P478 | volume | 30 |
Search more.